PubMed Health⌕ Search

PubMed · 15028004

Varying risk comparison elements: effects on public reactions.

Abstract

Expanding a limited empirical base on effects of risk comparisons, a pilot experiment explored how varying elements of such comparisons might influence public response. The scenario used was a hypothetical trial of an asbestos-installing firm for putting students and staff at a junior high school at "unreasonable risk," first used by Slovic et al. (1990). Study participants played the role of jurors in the trial, asked to rate the risk, the firm's guilt, whether it should be made liable for future health effects, whether the school should be occupied in its current condition, and whether the asbestos should be removed at a cost of 3 million dollars. Opportunity samples of New Jersey residents (n= 309) received information intended to vary four comparison attributes: number of dimensions of comparison; single versus multiple ways of expressing mortality; a narrative to explain and justify the risk comparison; and the hypothetical role of the participant (juror vs. parent). The dependent variable was a hazard scale constructed from four of the five postcomparison judgments. ANOVA found format variations swamped in their effect by concern about asbestos, with the absence of a narrative and the parental role being the only attributes that increased negative risk reactions. Multiple regression analyses found that multidimensionality, narrative, role, and the presence of any risk comparison at all had significant effects when these (plus death formats) were the only independent variables. However, only multidimensionality (which increased negative reactions) retained significance when asbestos concern, risk beliefs (no safe level of exposure to a carcinogen; any exposure leads to cancer), and demographic variables were added to the analysis. Concern and risk beliefs alone explained 33% of variance in hazard scores; adding demographics and risk comparison variables only raised explained variance to 36% (having children at home and being exposed to multidimensional risk comparisons raised scores; age and income lowered them). The results underline the potentially small effect of risk comparison information on risk views (at least between subjects), but offer some insight into aspects of message design left unexplored in empirical literature to date.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Branden B Johnson. 2004. Varying risk comparison elements: effects on public reactions.. https://doi.org/10.1111/j.0272-4332.2004.00415.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗